Study of cardiovAscular Contrasted Phenotypes in Patients With FamIliaI hypercholesteRolemia

• Patient agreeing to sign the consent of the study and the consent of biocollection
• Patient suffering from a familial hypercholesterolemia with a clinically-biologic score DLCN (Dutch Lipid Clinic Network, Annex 2)> 8 and / or a causative mutation identified in the LDL receptor genes, apolipoprotein B100 or Of PCSK9.
• Men ≥ 40 years of age; Female ≥ 50 years
• Patient affiliated to an existing social insurance

The inclusion criteria to be met in the population with known coronary atheroma:

• Subject in secondary prevention of an atheromatous disease: coronary event or ischemic heart disease, irrespective of the result of the coronary calcium score; Ischemic stroke with proven carotid atheromatosis; revascularization (angioplasty, bypass surgery) or amputation in PAD
• Primary prevention topic CV with calcium score ≥ 400 Agatston units

Inclusion criteria to be met in the population without cardiovascular risk:

• No cardiovascular event (including MI, coronary revascularization, angina, stroke \&, Transiant ischemic attack of atheromatous origin, PAD) with: For women between 50 and 65 years, a nil calcium score * For women between 65 and 75 years of age, a calcium score** ≤ 10 Agatston units For women over 75 years of age, a calcium score** ≤ 20 Agatston units For men between 40 and 55 years of age, a nil calcium score* for men For men between 55 and 70 years of age, a calcium score** ≤ 10 Agatston units For men over 70 years of age, a calcium score** ≤ 20 Agatston units

• 40 year old men and 50 year old women: less than 6 months old
• 41 year old men and 51 year old women: under 1 year old
• 42 year old men and 52 year old women: under 2 years old
• 43 year old men and 53 year old women: under 3 years old

• 44 year old men and 54 year old women: under 4 years old

  • Less than 5 years

Inclusion criteria to be met in the related population with familial hypercholesterolemia :

• Patient agreeing to sign the consent of the study and the consent of biocollection
• Patient suffering from a familial hypercholesterolemia with a clinically-biologic score DLCN (Dutch Lipid Clinic Network, Annex 2)> 8 and / or a causative mutation identified in the LDL receptor genes, apolipoprotein B100 or Of PCSK9.
• Men or Female ≥ 30 years
• Patient affiliated to an existing social insurance

Inclusion criteria to be met in the related population without familial hypercholesterolemia :

• Patient agreeing to sign the consent of the study and the consent of biocollection
• Patient not suffering from a familial hypercholesterolemia related to one of the members of the population suffering from familial hypercholesterolemia without cardiovascular risk
• Men or Female ≥ 18 years
• Patient affiliated to an existing social insurance

Exclusion Criteria:

• Subject suffering from active cancer or progressive neoplasia
• Subject treated with recent corticosteroid therapy
• Subjects with unsubstituted or poorly controlled hypothyroidism (TSH> normal)
• Subject receiving immunosuppressive or anti-cancer treatment
• Subject refusing to participate
• Subjects under tutelage, curatorship or a safeguard of justice or without social insurance

The exclusion criterion for all populations except the related population without familial hypercholesterolemia:

• Subject with no "definite" familial hypercholesterolemia according to the DLCN score (≤8), after auction. The purpose of the auction will be to rule on the causal nature of an identified mutation.